OS Therapies Incorporated
AMEX:OSTXBiotechnology
+$0.10 today
- Market cap
- $53.83M
- Beta
- -0.95
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$0.91
Volume 0.50M
Average 0.71M
OSTX Operating Income
Profit from core operations after operating expenses, before interest and taxes.
OS Therapies IncorporatedAMEX: OSTX
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$10.17M, compared with -$5M a year earlier. Trailing-twelve-month operating income was -$33.87M.
Context
- Operating income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 3 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -321.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$10.17M+15.2% QoQ
- Last fiscal yearDec 2025
- -$28.71M-321.3% YoY
- LTMMar 2026
- -$33.87M-202.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -103.4% | +100.0% | +203.4 pp |
| 1 year | -321.3% | +100.0% | +421.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (28.71M) USD
- Year-over-year change
- -321.3%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (28.71M) | -321.3% |
| FY2024 | 2024-12-31 | (6.81M) | -56.9% |
| FY2023 | 2023-12-31 | (4.34M) | +2.3% |
| FY2022 | 2022-12-31 | (4.45M) | +8.1% |
| FY2021 | 2021-12-31 | (4.84M) | — |
Operating Income vs competitors
How OSTX compares with its peers on the latest reported figures
- OSTX's LTM Mar 2026 operating income of -$33.87M is the 6th highest of the 9 companies compared; the peer median is -$22.97M.
- Its year-over-year change of -202.9% is the lowest of 8, against a peer median of +2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$12.84M | -37.2% | — | — | |
| LTM Mar 2026 | -$12.9M | -15.3% | — | 912.4% | |
| LTM Mar 2026 | -$17.19M | +2.1% | — | 749.7% | |
| LTM Mar 2026 | -$20.38M | -42.0% | — | — | |
| LTM Jun 2026 | -$25.57M | +65.0% | — | 121.8% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$33.87M | -202.9% | — | — |
| LTM Mar 2026 | -$34.01M | +41.4% | — | — | |
| LTM Jun 2024 | -$36.99M | — | — | 4534.8% | |
| LTM Mar 2026 | -$60.57M | +20.8% | — | 18182.8% | |
| Peer median (excluding OSTX) | -$22.97M | +2.1% | — | 912.4% | |
Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.16M | 805 | 4.22K | 2.78K | 363.09K |
| Gross Profit | (1.16M) | (805) | (4.22K) | (2.78K) | (363.09K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 2.17M | 3.29M | 3.22M | 2.84M | 16.36B |
| Selling, General & Admin | 1.5M | 1.15M | 1.12M | 3.97M | 12.34B |
| Operating Expenses | 3.68M | 4.45M | 4.34M | 6.81M | 28.34M |
| Depreciation & Amortization | 805 | 805 | 4.22K | 2.78K | 363.09K |
| EBITDA | (4.84M) | (4.45M) | (4.34M) | (6.83M) | (28.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (4.84M) | (4.45M) | (4.34M) | (6.81M) | (28.71M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 249 |
| Interest Expense | 2.58M | 1.81M | 3.45M | 2.05M | 0 |
| Other Income / Expenses | (2.58M) | (1.81M) | (3.45M) | (2.07M) | (48.14K) |
| Income Before Tax | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (7.42M) | (6.25M) | (7.79M) | (8.88M) | (28.75M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| EPS (Diluted) | (0.33) | (0.28) | (0.39) | (0.52) | (0.98) |
| Weighted Avg Shares | 23.1M | 23.1M | 20.05M | 20.87M | 29.25M |
| Weighted Avg Shares (Diluted) | 23.1M | 23.1M | 20.05M | 20.87M | 29.25M |
OS Therapies Incorporated
AMEX:OSTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.